Examining Policies to Promote Development of Antimicrobial Drugs

2017-07-14T05:23:48-06:00May 18th, 2017|Viewpoints|

In the latest post on the IVI-sponsored Health Affairs featured blog series, Seth Seabury and Neeraj Sood examine the challenges to addressing the significant threat that antimicrobial resistant infections pose to human health. In their commentary, Seabury and Sood focus on three of the most commonly proposed policies to promote the development of new antimicrobials: market entry awards, exclusivity extensions and priority review vouchers.

The authors conclude that a “hybrid approach that combined a priority review voucher with a briefer exclusivity extension might be an effective compromise that lowered some of the cost, but these should be coupled with additional efforts to prevent overuse of any antimicrobials developed.”

Read more here.

About the Health Affairs/IVI Featured Blog Series: Drugs and Medical Innovation — In partnership with Health Affairs, IVI is proud to sponsor the “Drugs and Medical Innovation” blog series. On an ongoing basis, articles in this series will explore topics such as value-based reimbursement, drug policy and pricing, balancing short-term access against long-term rates of innovation, and other relevant issues. Our goal is to create an open forum for sharing ideas and debating issues in these areas, extending the discussion to a broader audience.